ANESTAGEL™

A NEW, OPIOID-FREE PAINKILLER

  • Pre-Clinical studies completed; FDA pre-IND next
  • AniGel: Multi-billion $ Veterinary Care Opportunity
  • Phase 1 Clinical Study manufacturing line underway

 

InSitu Biologics is currently in the pre-clinical stage

Invest in InSitu Biologics

We intend to close our Regulation A+ offering for the last time no later than Nov 30, 2019. The share price remains at $8.20 and prospective investors are encouraged to visit our Offering page to learn more and begin their investment:

Learn More About Investing

Biotech Investor Presentation in St. Paul

Please join us for a presentation with drinks and appetizers on Thursday, Nov. 21st from 5:00 -7:00 PM at Town and Country Club in St. Paul. RSVP required:

Learn More & RSVP

Who We Are

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more.

Latest News & Updates

Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

See our study at the Journal of Pain Research

Timeline

  • 2016

    Q1
    Filed additional patent(s)

    Q2
    White Paper published

    Q3
    Completed maximum dosing study with no toxicity

    Q4
    Presented at PODD-Boston

  • 2017

    Q1
    Completed first GLP study

    Q2
    Proved more pain relief compared to Exparel in pre-clinical study

    Q3
    GLP publication accepted

    Q4
    Raised over $400k

  • 2018

    Q1
    Completed Financial Audit
    Converted all debt
    Filed $10,000,000 RegA+ Offering

    Q2
    Launch RegA+ Offering
    Announce GLP Paper by Hutchins & Taylor

    Q3
    Begin Phase 1 program manufacturing

    Q4
    Announce final GLP Study results

  • 2019

    Q1
    SEC valuation incorporating Animal Care Market opportunity

    Q2
    Submit GLP results for Peer-Review

    Q3
    FDA Pre-IND meeting

    Q4
    Expect approval for Phase 1 Clinical Study of AnestaGel